Zydus Wellness Ltd Share Price (ZYDUSWELL)

Zydus Wellness Reports Strong Revenue Growth in FY23 - 16 Apr, 2024

Zydus Wellness reported a strong growth in revenue for FY23 and has a lower P/E ratio compared to the industry average. La Renon joined ChrysCapital's list of Indian healthcare companies which includes Zydus Cadila.

Health Food Drinks Market in India Worth Over $1 Billion - 15 Apr, 2024

Zydus Wellness' Complan is one of the popular health food drinks in India, marketed as a nutritional drink. The market for such malt-based milk drinks has been growing steadily and is worth over $1 billion.

Zydus Lifesciences Receives Four Observations from USFDA After Inspection - 28 Mar, 2024

Zydus Lifesciences receives four observations from the USFDA following an inspection of its Onco Injectable manufacturing plant in Ahmedabad. Despite this, the company's share price remains stable as it posts a strong financial performance in Q1-Q3 FY24.

Zydus Lifesciences Receives Observations from USFDA - 27 Mar, 2024

The US Food and Drug Administration (USFDA) has issued four observations to Zydus Lifesciences' SEZ Onco Injectable manufacturing plant in Ahmedabad. The company will work closely with the USFDA to address and resolve the observations.

Zydus Lifesciences Shares Surge on FDA Approval - 26 Mar, 2024

Zydus Lifesciences' stock value surges as it receives tentative approval from the US Food and Drug Administration (FDA) for its Letermovir tablets, used to prevent disease caused by a virus called cytomegalovirus. The approval marks a major milestone for Zydus Lifesciences and signals sustained investor confidence.

Zydus Receives Tentative Approval for Letermovir Tablets - 23 Mar, 2024

Zydus Lifesciences has received tentative approval from the USFDA to market Letermovir tablets, used to prevent disease caused by cytomegalovirus. The drug will be manufactured at their facility in Ahmedabad SEZ, India. Annual sales of Letermovir tablets were $289.5 million in the US. Shares rose 0.79% to close at Rs 999.50 on Friday.

Zydus Wellness Ltd's Debt and Balance Sheet Analysis - 20 Mar, 2024

Zydus Wellness Ltd has a net debt of about ₹979.0m with low net debt to EBITDA ratio of only 0.34. Its EBIT covers its interest expense 13.6 times over, but it has seen a plunge in EBIT by 14% in the last twelve months. The balance sheet is an area to focus on when analyzing debt.

Zydus Receives FDA Approval for Prostate Medication - 18 Mar, 2024

Zydus Wellness subsidiary, Zydus Lifesciences, has received final approval from the USFDA to market Finasteride and Tadalafil capsules for treating benign prostatic hyperplasia. The company is eligible for 180 days of CGT exclusivity.